NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Natural History Study of Patients with Excess Androgen

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Institute of Child Health and Human Development (NICHD)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 1 days
Max Age: 99 Years

Referral Letter Required


Population Exclusion(s)



Congenital Adrenal Hyperplasia (CAH);
Familial Male Precocious Puberty (FMPP);
21-Hydroxylase Deficiency;
Adrenal Insufficiency;
Natural History

Recruitment Keyword(s)

Congenital Adrenal Hyperplasia;
Familial Male Precocious Puberty;


Congenital Adrenal Hyperplasia (CAH);
Familial Male-Limited Precocious Puberty (FMPP)

Investigational Drug(s)


Investigational Device(s)




Supporting Site

National Institute of Child Health and Human Development

This study will evaluate and gather information in patients with genetic causes of too much androgen (male-like hormone) in order to better understand the effects of too much androgen and describe problems associated with it. Too much androgen in childhood, if untreated, results in rapid growth and early puberty with early cessation of growth and short stature in adulthood. Too much androgen in adulthood may result in infertility, and women may have excess facial hair, acne and a more male-like appearance. Excess androgen may also affect mood and behavior and possibly the secretion of other hormones, such as insulin. Two genetic diseases that result in early childhood androgen excess are congenital adrenal hyperplasia (CAH) and familial male-limited precocious puberty (FMPP).

Patients with known or suspected CAH due to 21-hydroxylase deficiency, 11- hydroxylase deficiency, or 3-beta-hydroxysteroid dehydrogenase deficiency and males with known or suspected FMPP may be eligible for this study. Patients with both classic and non-classic CAH are eligible, and patients with androgen excess of unknown cause may be eligible.

Participants undergo the following procedures:

-Medical history and physical examination.

-Fasting blood tests for analysis of hormones, blood chemistries including blood sugar and cardiovascular risk factors such as lipids.

-Oral glucose tolerance test for patients with elevated insulin levels. For this test, a catheter (plastic tube) is placed in a vein in the patient's arm. The patient drinks a sugar-containing fluid and blood samples are collected through the catheter at intervals starting with drinking the solution, and then 30, 60 and 120 minutes after drinking the solution.

-24-hour urine collection to measure hormone levels in the urine.

-DNA testing for patients with 21-hydroxylase deficiency to help identify the type of genetic mutation responsible for the disease.

-X-ray of the left hand to measure bone age in growing children. The x-ray is used to determine how far into puberty the child is and how much growth potential is left in the bones.

-A pelvic ultrasound in females and testicular ultrasound in males to evaluate the size and development of the gonads (ovaries in females and testes in males).

-Cognitive and psychological tests, including an IQ test and evaluation of memory, achievement and behavior.

-Other tests and evaluations based on medical need.

The schedule for these procedures varies. In a part of the study involving only patients with CAH, growing children are evaluated twice (once in childhood and once after reaching adult height), and adults are evaluated once. In another part of the study involving patients with CAH and FMPP, growing children are seen twice a year, and adults and children who have reached adult height may be seen annually. Additional visits may be scheduled if medically indicated. In this part of the study, females are asked to keep a record of their periods after their first menstrual cycle.

--Back to Top--



1) Males, ages 0 - 99 with known or suspected FMPP or

2) Patients (males and females, ages 0 - 99) with known or suspected (based on hormonal, clinical and/or genetic testing) CAH of any type.

3) Patients with excess androgen of unknown etiology or

4) Relatives of patients in this protocol.


1) Females with isolated polycystic ovary syndrome. If, following a diagnostic work-up, a patient is determined to have PCOS as the only cause of her hyperandrogenism; she will no longer be followed on this protocol.

2) Patients with significant non-endocrine medical conditions.

3) Females who are pregnant at the time of initial enrollment.

--Back to Top--


Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet. 2005 Jun 18-24;365(9477):2125-36.

Grumbach MM, Shaw EB. Further studies on the treatment of congenital adrenal hyperplasia with cortisone: IV. Effect of cortisone and compound B in infants with disturbed electrolyte metabolism, by John F. Crigler Jr, MD, Samuel H. Silverman, MD, and Lawson Wilkins, MD, Pediatrics, 1952;10:397-413.Pediatrics. 1998 Jul;102(1 Pt 2):215-21.

Weise M, Mehlinger SL, Drinkard B, Rawson E, Charmandari E, Hiroi M, Eisenhofer G, Yanovski JA, Chrousos GP, Merke DP. Patients with classic congenital adrenal hyperplasia have decreased epinephrine reserve and defective glucose elevation in response to high-intensity exercise. J Clin Endocrinol Metab.2004 Feb;89(2):591-7.

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Deborah P. Merke, M.D.
National Institute of Child Health and Human Development (NICHD)
NIHBC 10 - CRC BG RM 3-2740
(301) 496-0718

Deborah P. Merke, M.D.
National Institute of Child Health and Human Development (NICHD)
NIHBC 10 - CRC BG RM 3-2740
(301) 496-0718

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: TTY Users Dial 7-1-1

Clinical Trials Number:


--Back to Top--